Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | NOS3 | P29474 | 1/20 | 0.44 |
| ▸ | NOS1 | P29475 | 1/20 | 0.44 |
| ▸ | NOS2 | P35228 | 1/20 | 0.44 |
| ▸ | EP300 | Q09472 | 1/20 | 0.42 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.42 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | PLAT | P00750 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 2/20 | 0.40 |
| ▸ | GABRP | O00591 | 1/20 | 0.40 |
| ▸ | GABRD | O14764 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.40 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31086650 | 1.00 | IDO1 (0.44) | IDO1NOS3NOS1NOS2EP300 | |
| SCHEMBL12596117 | 0.87 | HCK (0.46) | IDO1NOS3NOS1NOS2EP300 | |
| SCHEMBL17014135 | 0.86 | NOS3 (0.45) | NOS3NOS1NOS2PLAUPLAT | |
| SCHEMBL365975 | 0.83 | ABCB1 (0.48) | IDO1EP300KAT8PLAUPLAT | |
| SCHEMBL17017685 | 0.82 | MAPK14 (0.40) | NOS3NOS1NOS2PLAUPLAT | |
| SCHEMBL22898278 | 0.82 | PLAU (0.40) | IDO1EP300KAT8PLAUPLAT | |
| SCHEMBL22898270 | 0.81 | ALDH1A1 (0.41) | IDO1EP300KAT8PLAUPLAT | |
| SCHEMBL31086675 | 0.80 | DYRK1A (0.41) | NOS3NOS1NOS2GABRPGABRD | |
| SCHEMBL1981976 | 0.80 | DYRK1A (0.41) | NOS3NOS1NOS2GABRPGABRD | |
| SCHEMBL31086846 | 0.80 | LTA4H (0.39) | IDO1NOS3NOS1NOS2EP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11634406-B2 | Inhibitor of p38 MAP kinase | RESPIVERT LTD. (GB) | 2023-04-25 | — | — | US | disclosed |
| US-11142515-B2 | Pyrazolyl-ureas as kinase inhibitors | RESPIVERT LIMITED (GB) | 2021-10-12 | — | — | US | disclosed |
| US-11142515-B2 | Pyrazolyl-ureas as kinase inhibitors | RESPIVERT LIMITED (GB) | 2021-10-12 | — | — | US | disclosed |
| CN-113264921-A | Pyrazolyl-ureas as kinase inhibitors | 瑞斯比维特有限公司 | 2021-08-17 | — | — | CN | disclosed |
| US-20210179584-A1 | INHIBITOR OF p38 MAP KINASE | RESPIVERT LIMITED (GB) | 2021-06-17 | — | — | US | disclosed |
| CN-106573914-B | Pyrazolyl-ureas as kinase inhibitors | 瑞斯比维特有限公司 | 2021-05-28 | — | — | CN | disclosed |
| EP-3418279-B1 | DRY POWDER PHARMACEUTICAL FORMULATION | RESPIVERT LTD (GB) | 2021-01-20 | — | — | EP | disclosed |
| EP-3418279-B1 | DRY POWDER PHARMACEUTICAL FORMULATION | RESPIVERT LTD (GB) | 2021-01-20 | — | — | EP | disclosed |
| US-10815217-B2 | Inhibitor of p38 MAP kinase | RESPIVERT LTD. (GB) | 2020-10-27 | — | — | US | disclosed |
| EP-3357919-B1 | AROMATIC HETEROCYCLIC COMPOUNDS AS ANTIINFLAMMATORY COMPOUNDS | RESPIVERT LTD (GB) | 2019-11-20 | — | — | EP | disclosed |
| WO-2011070368-A1 | ANTIVIRAL USE OF UREA COMPOUNDS | RESPIVERT LIMITED (GB) | 2011-06-16 | — | — | WO | disclosed |
| WO-2011070368-A1 | ANTIVIRAL USE OF UREA COMPOUNDS | RESPIVERT LIMITED (GB) | 2011-06-16 | — | — | WO | disclosed |
| WO-2011070369-A1 | INHIBITORS OF HEMOPOIETIC CELL KINASE (P59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION | RESPIVERT LIMITED (GB) | 2011-06-16 | — | — | WO | disclosed |
| WO-2011070369-A1 | INHIBITORS OF HEMOPOIETIC CELL KINASE (P59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION | RESPIVERT LIMITED (GB) | 2011-06-16 | — | — | WO | disclosed |
| WO-2010067131-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010067131-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010038085-A2 | P38 MAPK KINASE INHIBITOR | RESPIVERT LIMITED (GB) | 2010-04-08 | — | — | WO | disclosed |
| WO-2010038085-A2 | P38 MAPK KINASE INHIBITOR | RESPIVERT LIMITED (GB) | 2010-04-08 | — | — | WO | disclosed |
| WO-2010038086-A2 | NOVEL COMPOUNDS | RESPIVERT LIMITED (GB) | 2010-04-08 | — | — | WO | disclosed |
| WO-2010038086-A2 | NOVEL COMPOUNDS | RESPIVERT LIMITED (GB) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10815217-B2 | Inhibitor of p38 MAP kinase | MAPK1, MAPKAPK2, MAP3K1 | IDO1 842/4885NOS3 1732/4885NOS1 827/4885 |
| US-20210179584-A1 | INHIBITOR OF p38 MAP KINASE | MAPK1, MAPKAPK2, MAPK10 | IDO1 3371/4885NOS3 471/4885NOS1 172/4885 |
| US-11142515-B2 | Pyrazolyl-ureas as kinase inhibitors | MAPK1, MAP3K1, MAP3K8 | IDO1 2064/4885NOS3 118/4885NOS1 104/4885 |
| US-11634406-B2 | Inhibitor of p38 MAP kinase | MAPK1, MAPKAPK2, MAPK10 | IDO1 3371/4885NOS3 471/4885NOS1 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.